CIALIS - AN OVERVIEW

In October 2007, the FDA announced that the labeling for all PDE5 inhibitors, which includes tadalafil, requires a much more prominent warning from the prospective threat of sudden hearing loss as the results of submit-advertising reports of temporary deafness affiliated with usage of PDE5 inhibitors.[19]Unique interactions may cause diverse effect